Oncolytic virus OVV-03 enhances CAR-T cell therapy against glioblastoma via immune modulation and specific HER2 upregulation.

ABSTRACT: Glioblastoma (GBM) remains therapeutically challenging due to treatment resistance and immunosuppression. Oncolytic virotherapy offers a promising strategy. This study engineered OVV-03, a novel HER2-armed oncolytic vesicular stomatitis virus (VSV), and evaluated its efficacy against GBM. OVV-03 demonstrated potent infectivity and cytotoxicity in GBM cell lines and patient-derived cells, inducing caspase-dependent apoptosis and suppressing proliferation/clonogenicity. In murine GBM models, OVV-03 significantly suppressed tumor growth, improved survival, and enhanced CD8⁺ T cell infiltration. Single-cell RNA sequencing revealed OVV-03 remodels the tumor immune microenvironment by boosting cytotoxic T cell activity and inhibiting immunosuppressive pathways, notably PD-L1/PD-1 signaling. Mech

SUBMITTER: Tang Y 

PROVIDER: S-EPMC12785206 | biostudies-literature | 2026 Dec

REPOSITORIES: biostudies-literature